{"id":"d0459dea435b","type":"article","url":"https://hartvaat.nl/2017/11/01/rehospitalisatie-na-intermitterend-levosimendan-bij-gevorderd-hartfalen-meta-ana/","title":"Rehospitalisatie na intermitterend levosimendan bij gevorderd hartfalen: meta-analyse","title_en":"Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta-analysis of randomized trials.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":["acuut-hartfalen","pathfinder-trial","step-hfpef"],"journal":"ESC heart failure","doi":"10.1002/ehf2.12177","source_url":"https://doi.org/10.1002/ehf2.12177","authors":["Simona Silvetti","Alessandro Belletti","Antonella Fontana","Piero Pollesello"],"significance":6,"published":"2017-11-01","source_date":"2017-11-01","image":"","kennis":[],"congress":"","summary_en":"This meta-analysis evaluated intermittent levosimendan administration in advanced heart failure, assessing whether repeated infusions improve quality of life and reduce rehospitalization in patients with refractory disease.","created":"2026-07-03T10:26:58Z","updated":"2026-07-03T18:38:35Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse van gerandomiseerde trials naar intermitterend levosimendan bij gevorderd hartfalen. Onderzoekt of herhaalde toediening ziekenhuisopnames vermindert.","abstract_original":"AIMS: Intermittent levosimendan administration has been suggested to improve survival in patients with advanced heart failure (AdHF). Quality of life is a key issue for AdHF patients and is negatively affected by frequent hospitalizations. METHODS AND RESULTS: CENTRAL, Google Scholar, MEDLINE/PubMed, Scopus, and the Cochrane Central Register of clinical trials (updated 15/1/2017) were searched for randomized controlled trials investigating the effect of intermittent levosimendan administration in patients with AdHF. The primary outcome was the number of patients requiring rehospitalization 3 months after the end of treatment. A total of 319 patients from six trials were included. Overall pooled analysis showed that the use of levosimendan was associated with a significant reduction in the number of rehospitalizations at 3 months: 33/207 (16%) vs. 39/113 (35%), risk ratio 0.40, 95% confidence interval 0.27-0.59, P < 0.001, I2  = 0%. This result was confirmed by sensitivity analyses. CONCLUSIONS: Within the limitations of this meta-analysis including also studies in which endpoints were not independently adjudicated and not clearly specified, repetitive or intermittent administration of levosimendan for patients with AdHF was associated with a reduction in the rehospitalization rate at 3 months. Large, high-quality randomized controlled trials are needed to confirm this finding."}